ルシード ダイアグノースティクスに関するコメント

$ルシード ダイアグノースティクス(LUCD.US)$ Lucid Diagnostics Announces Peer-Reviewed Publication of Positive Data From National Cancer Institute-Sponsored, Prospective, Multicenter Clinical Validation Study of EsoGuard Esophageal Precancer Testing
PR Newswire· 2 mins ago

$ルシード ダイアグノースティクス(LUCD.US)$
NEWS
Lucid Diagnostics Announces Peer-Reviewed Publication of Positive Data from National Cancer Institute-Sponsored, Prospective, Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing
The peer-reviewed publication of positive data from a National Cancer Institute-sponsored study enhances Lucid Diagnostics' reputation and credibility in the medical diagnostics field.
EsoGuard's demonstration of unprecedented early precancer detection with 89...

$ルシード ダイアグノースティクス(LUCD.US)$ Lucid Diagnostics posted Q4 revenues of $1 million, marking a 33% increase from Q3 and a 829% increase annually.
Non-GAAP net loss for the quarter was $9.9 million, showing a slight increase from Q3 but a year-over-year decrease of $700,000.
The company had a year-end cash balance of $18.9 million, supported by a recent financing of $18.1 million.
Approximately 50% of the claims submitted have been adjudicated, with an averaging payment of $1,800.
The projected re...

$ルシード ダイアグノースティクス(LUCD.US)$ Lucid Diagnostics Executes Contract to Provide EsoGuard Esophageal Precancer Testing as a Covered Benefit for 9/11 Responders and Survivors
PR Newswire· 1 min ago
The World Trade Center Health Program will now cover the cost of EsoGuard testing for its more than 120,000 participants at almost 2.5K per billable test

$ルシード ダイアグノースティクス(LUCD.US)$ Lucid Diagnostics: 1-for-15 Reverse Stk Split to Be Effective as of Market Open on Dec 7 >LUCD
Dow Jones· 1 min ago

$ルシード ダイアグノースティクス(LUCD.US)$ based off analysts rating, I will hold for the walk back up

Monday, December 27, 2021
By Danilo
$イノヴェージ ホールディング(INNV.US)$ $ルシード ダイアグノースティクス(LUCD.US)$ $イノヴィド コーポ(CTV.US)$ $チェサピーク・エナジー(CHK.US)$

$ルシード ダイアグノースティクス(LUCD.US)$ how much people will buy this one instead of $ルシード グループ A(LCID.US)$?

$パブメッド(PAVM.US)$ Another 52 week low for $ルシード ダイアグノースティクス(LUCD.US)$ we're going to keep going down until it finds a bottom.   My guess is the test centers are empty or this would be ticking up.  My hope is they are not burning through the 60 million too fast.  If they can get through a few quarters and grow tests, they become a real buyout target.